Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)

This study has been withdrawn prior to enrollment.
(Because funding was not secured, the study was never initiated. 0 subjects enrolled)
Information provided by (Responsible Party):
J. Peter Rubin, MD, University of Pittsburgh Identifier:
First received: December 19, 2012
Last updated: October 19, 2016
Last verified: October 2016
The investigators will assess changes in breast appearance, graft retention and quality of life over one year in patients who have received direct autologous adipose tissue injection for the treatment of objectionable post-surgical breast deformities. These patients have undergone the resection of breast tissue to treat either benign or malignant breast disease.

Condition Intervention
Breast Cancer
Mastectomy, Segmental
Procedure: Autologous Fat Graft

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)

Resource links provided by NLM:

Further study details as provided by J. Peter Rubin, MD, University of Pittsburgh:

Primary Outcome Measures:
  • Breast Tissue Volume/Appearance (Graft Retention) [ Time Frame: Through 12 months following procedure ]
    Assess breast appearance and soft tissue volume before and after autologous fat grafting utilizing 2D / 3D digital photography and a physician rating scale to determine graft retention through 12 months following fat grafting procedure.

Secondary Outcome Measures:
  • Patient Satisfaction [ Time Frame: 6 months after procedure ]
    Measure patient satisfaction with use of quality of life questionnaires (SF-36 and BREAST-Q) before and after autologous fat grafting.

Other Outcome Measures:
  • Assess Cellular Properties of Graft [ Time Frame: Sample collected at time of procedure ]

    Preadipocyte yield: The number of cells isolated per gram of adipose tissue will be determined using a hemacytometer.

    Preadipocyte Viability: Cell viability will be determined using the Live/Dead assay.

    Preadipocyte Proliferation: Cellular proliferation of preadipocytes will be assessed with the CyQUANT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA) at 48 and 96 hours.

    Preadipocyte Differentiation: The assessment of the potential of the preadipocytes to differentiate into adipogenic cell types will be assessed

Enrollment: 0
Study Start Date: July 2011
Study Completion Date: October 2014
Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Autologous Fat Graft
Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
Procedure: Autologous Fat Graft
Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.

Detailed Description:

During the past decade there has been increased awareness of the potential of free adipose cell grafting to treat a variety of problems in both reconstructive and cosmetic plastic surgery. There have been encouraging reports describing the use of autologous fat grafts (fat tissue harvested by standard liposuction techniques in a given patient and then re-injected at another site) for treating breast deformities in the setting of benign and previously treated malignant breast problems.

There has been a corresponding large scale laboratory investigation effort into the potential of adipose derived stem cells (ADSC's) harvested during liposuction and induced to differentiate into various cell types in the mesenchymal cell line. The potential clinical utility of these cells in the treatment of patients who present with a breast deformity after segmental mastectomy (lumpectomy) and radiation therapy has been described, but not studied in rigorous prospective manner.

The investigators believe that the clinical use of these autologous fat cell grafts have unique advantages in the treatment of breast deformities. The technique is minimally invasive, easily repeated and is associated with minimal surgical morbidity (indeed it may have the advantage of improving the appearance of both the breast deformity and the area from which they are harvested), it typically displays a rapid recovery, a complication rate that is no greater (and probably less than ) established and currently used surgical treatment(s) of these breast problems, and is oncologically safe.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 through 70 years of age inclusive and able to provide informed consent and
  • Subject is 6 months post chemotherapy or radiation treatment and is scheduled for physician evaluation for a standard of care breast fat graft procedure.
  • Per PI's discretion is stable post-surgery or who has a benign breast deformity or post segmental breast deformity
  • Willing and able to comply with the study schema for research procedures.

Exclusion Criteria:

Age less than 18 years

  • Inability to provide informed consent
  • Active chemotherapy or radiation therapy treatment for cancer diagnosis
  • Not clinically stable to have a surgical intervention
  • Active infection anywhere in the body
  • Known coagulopathy
  • Pregnancy
  • Per the PI's discretion, subject is not a candidate for participation in this clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01756092

United States, Pennsylvania
UPMC Center for Innovation in Restorative Medicine
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Principal Investigator: J. Peter Rubin, MD University of Pittsburgh
  More Information

Rigotti, G. Oncologic Safety of Adipose Derived Stem Cell Grafts in the Treatment of Post-Lumpectomy Patients. Presented at the 88th Annual Meeting of the American Society of Plastic Surgeons

Responsible Party: J. Peter Rubin, MD, Principal Investigator, University of Pittsburgh Identifier: NCT01756092     History of Changes
Other Study ID Numbers: PRO10020385
Study First Received: December 19, 2012
Last Updated: October 19, 2016

Keywords provided by J. Peter Rubin, MD, University of Pittsburgh:
Breast Cancer
Mastectomy, Segmental

Additional relevant MeSH terms:
Congenital Abnormalities processed this record on May 25, 2017